Objective(s):In this study, 166Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) (166Ho-PDTMP) complex  was prepared as a bone palliation agent. Materials and Methods:The complex was successfully prepared using an in-house synthesized EDTMP ligand and 166HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural Ho(NO3)3 samples  followed by radio...

Background: Skin cancer can be treated by various methods. Electron radiotherapy has been a useful therapeutic modality in the treatment of skin cancers in areas which are difficult to cure by other methods. Depth dose distribution of 166Ho using VARSKIN2 code is presented in this work. Material and Methods: Depth dose distribution of 166Ho was calculated, using VARSKIN2 code by adding...

intoduction: therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. among some therapeutic radiopharmaceuticals, 166ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethylene phosphonic acid (166ho-dotmp) is us...

In this study, production, quality control and biodistribution studies of 166Ho-zoledronate have been presented as a possible bone marrow ablative agent. Ho-166 chloride was produced by thermal neutron irradiation of natural 165Ho(NO3)3 samples. 166Ho-zoledronate complex was prepared by adding the desired amount of zoledronate solution (0.2 mL, 150 mg/ml in 1 M NaOH) to appropriate amount of th...

introduction: using beta emitter radionuclide is a useful therapeutic modality in the treatment of skin cancers in areas which are difficult to cure by other methods. the aim of this research is to evaluate the tissue response to beta rays of 166ho and determine the feasibility of beta emitting radionuclide for treatment of skin cancers. methods: in this work, we have calculated depth dose dist...

Anhydrous (99.99%) TbCl3 was obtained from Aldrich (Milwaukee, WI, USA) and used without further purifications. It was handled in an argon-filled dry box with a water content < 2 ppm and an oxygen content < 1 ppm. A 166Ho radiation source (2.27 MBq) was used because of its desirable decay characteristics (t1/2 = 1200y, up to 8 photons per disintegration, more than 10% branching ratio). A multi-...

Introduction: The dosimetric characteristics of patch sources including 32P, 90Y, 188Re and 166Ho, which are employed for radionuclide skin therapy, have been evaluated in current study Materials and Methods: The patch sources understudy were modeled by MCNPX Monte Carlo code and corresponding depth dose distribution, transverse dose profile and isodose curves...

introduction: in this research, [166ho]holmium chitosan complex production is described in details, followed by determination of complex radiochemical purity, stability and biodistribution (after intra-articular injection) in wild-type male rats. finally a ho-166 based chitosan kit for ultimate radiosynovectomy as well as radiotherapy applications was developed.methods: 166ho-chitosan complex w...